00:02:42 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2024-10-31 Kvartalsrapport 2024-Q3
2024-07-11 Kvartalsrapport 2024-Q2
2024-06-28 Årsstämma 2024
2024-06-12 X-dag ordinarie utdelning QLINEA 0.00 SEK
2024-05-31 Kvartalsrapport 2024-Q1
2024-02-27 Bokslutskommuniké 2023
2023-11-02 Kvartalsrapport 2023-Q3
2023-07-13 Kvartalsrapport 2023-Q2
2023-07-03 Extra Bolagsstämma 2023
2023-06-13 Årsstämma 2023
2023-05-24 X-dag ordinarie utdelning QLINEA 0.00 SEK
2023-05-04 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-07-14 Kvartalsrapport 2022-Q2
2022-05-25 X-dag ordinarie utdelning QLINEA 0.00 SEK
2022-05-24 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-07-15 Kvartalsrapport 2021-Q2
2021-05-26 X-dag ordinarie utdelning QLINEA 0.00 SEK
2021-05-25 Årsstämma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-07-16 Kvartalsrapport 2020-Q2
2020-05-27 X-dag ordinarie utdelning QLINEA 0.00 SEK
2020-05-26 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-07-18 Kvartalsrapport 2019-Q2
2019-05-23 X-dag ordinarie utdelning QLINEA 0.00 SEK
2019-05-22 Årsstämma 2019
2019-05-03 Kvartalsrapport 2019-Q1
2019-02-14 Bokslutskommuniké 2018


ListaSmall Cap Stockholm
Q-Linea är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av instrument och förbrukningsartiklar. Produkterna används huvudsakligen vid behandling av infektionssjukdomar och blodförgiftning, och innefattar diagnostik- och analysverktyg, samt övrig grundläggande provhantering. Tekniken baseras på den så kallade ID- samt AST tekniken. Bolaget grundades 2008 och har huvudkontoret i Uppsala.
2024-02-09 08:30:00

Q-linea AB (publ) (OMX:QLINEA) today announces that the board has decided to place the Podler technology in a separate subsidiary so that Q-linea can focus on the company's main product ASTar. At the same time, the change makes it easier to be able to further develop Podler independent from Q-linea´s core business and in that way maximize the value of Podler.

"I think this is a good strategy by the board. It shows a clear focus on ASTar and at the same time opens possibilities to be able to further develop Podler outside of Q-linea and simplify for a partnership, sale, or continued development with separate financing of Podler", said Jonas Jarvius, president and CEO of Q-linea.

Podler is a technology that has been developed by Q-linea which enables the diagnosis of patients with blood infections to be speeded up. Today, all blood cultures need to be incubated in dedicated blood culture cabinets to be able to enrich bacteria and alert in the presence of bacteria in the blood. This enrichment step is crucial for follow-up tests such as rapid AST and ID analysis.

Today, this enrichment takes place in blood culture cabinets placed mainly in the microbiology laboratories of hospitals. This means that the samples must be transported, both within the hospital and from neighboring hospitals that do not have blood culture capacity. During transport, there is no or limited growth in the sample, which means that diagnostics does not start until the sample is loaded into the blood culture cabinet. The transport can often take over 10 hours, which can be life-threatening for patients with blood infections.

Podler can be seen as a portable blood culture cabinet and enables the initiation of sample analysis directly at the patient, resulting in large time savings.